Navigation Links
Peptimmune Presentations at Upcoming Events
Date:10/28/2008

CAMBRIDGE, Mass., Oct. 28 /PRNewswire/ -- Peptimmune, Inc., a privately held biotechnology company, announced today that President & CEO Thomas P. Mathers will provide an update on the Company's current phase Ib clinical trial for PI-2301 in multiple sclerosis patients at the three upcoming events:

1. BIO Investor Forum 2008. The presentation will take place on Wednesday,

October 29th, at 3:15 p.m. in the Pacific Room at the Palace Hotel in

San Francisco.

2. Oppenheimer 19th Annual Healthcare Conference. The presentation will

take place on Tuesday, November 4th, at 10:40 a.m. in the Louis XVI

Room at the Waldorf-Astoria Hotel in New York City.

3. Rodman & Renshaw 10th Annual Healthcare Conference. The presentation

will take place on Wednesday, November 12th, at 2:25 p.m. in the Adams

Room at the New York Palace Hotel in New York City.

PI-2301 is currently in a Phase Ib multiple-ascending dose, double-blind, placebo-controlled randomized study in subjects with multiple sclerosis. Following establishment of safety at potentially therapeutic doses and proof of pharmacologic mechanism, the Company plans to initiate its Phase II study in relapsing remitting multiple sclerosis patients in early 2009.

PI-2301 is a second-generation peptide copolymer from a similar compound class as Copaxone(R) (Teva Pharmaceuticals). PI-2301 has been designed to be more efficacious and more convenient (weekly versus daily dosing) than Copaxone for the treatment of multiple sclerosis. PI-2301 works through immune modulation by enhancing the regulatory response of the immune system and thereby controlling the pathogenic autoimmune response observed in some diseases. In a Phase I single ascending dose, double blind placebo controlled randomized study, all doses of PI-2301 were safe and well tolerated, and no serious adverse events were observed. Pharmacodynamic assays demonstrated evidence of immune exposure consistent with the pharmacologic mechanism of action for PI-2301, and dose-dependent pharmacokinetics was observed.

PI-2301 has been optimized using Peptimmune's novel platform peptide chemistry and, in preclinical studies, has shown to be more potent and effective than Copaxone in treating disease models for multiple sclerosis. PI-2301 has also shown efficacy in preclinical models of autoimmune diseases where immune modulation may be effective, such as Crohn's disease, rheumatoid arthritis, and autoimmune uveitis. Peptimmune has put in place high-quality synthesis and analytical methods that provide a superior level of batch-to-batch reproducibility in the manufacturing of PI-2301.

Over 400,000 Americans have multiple sclerosis (MS), and MS may affect over 2.5 million individuals worldwide. MS is an autoimmune disease in which the individuals' immune system responds against multiple components of nerve-insulating myelin. The effects of these immune-mediated attacks can range from relatively benign to somewhat disabling to devastating, as communication between the brain and other parts of the body is disrupted.

About Peptimmune

Peptimmune, Inc. is a privately held clinical stage biotechnology company focused on the development of peptide therapies to improve the management of chronic autoimmune and inflammatory disorders. The Company is in clinical development with second-generation therapeutics that are expected to result in safer and more effective products for multiple sclerosis and pemphigus vulgaris. Current investors include New Enterprise Associates, MPM Capital, Hunt Ventures, Boston Medical Investors, Silicon Valley Bank Capital, and Genzyme Corporation.


'/>"/>
SOURCE Peptimmune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Peptimmune Announces First Close of Series D Private Financing
2. Peptimmune Presentation at Upcoming World Congress on Treatment and Research in Multiple Sclerosis
3. Response Genetics Announces Presentations/Webcasts at Upcoming Investor Conferences
4. Juvaris BioTherapeutics Announces Six Scientific Presentations at Infectious Diseases Society of America (IDSA) Meeting October 6, 2007
5. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
6. Actelion Announces Multiple Presentations on Tracleer(R) and the REVEAL Registry at CHEST 2007
7. Response Genetics CEO to Discuss Advances in Optimizing Therapy through Pharmacogenomics as Part of a Series of Presentations at AACR-NCI-EORTC International Conference
8. CV Therapeutics Announces Presentations at American Heart Association Scientific Sessions 2007
9. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
10. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
11. Gen-Probe to Webcast Three Upcoming Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... , ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical ... mesothelioma. Their findings are the subject of a new article on the Surviving Mesothelioma ... in the blood, lung fluid or tissue of mesothelioma patients that can help point ...
(Date:6/23/2016)... 2016 A person commits a crime, and the ... track the criminal down. An outbreak of foodborne ... Administration (FDA) uses DNA evidence to track down the bacteria ... far-fetched? It,s not. The FDA has increasingly used a complex, ... foodborne illnesses. Put as simply as possible, whole genome sequencing ...
(Date:6/23/2016)...   EpiBiome , a precision microbiome engineering company, ... financing from Silicon Valley Bank (SVB). The financing will ... its drug development efforts, as well as purchase additional ... has been an incredible strategic partner to us – ... would provide," said Dr. Aeron Tynes Hammack , ...
(Date:6/23/2016)... 2016  Blueprint Bio, a company dedicated to identifying, ... community, has closed its Series A funding round, according ... "We have received a commitment from Forentis Fund ... to meet our current goals," stated Matthew Nunez ... to complete validation on the current projects in our ...
Breaking Biology Technology:
(Date:6/2/2016)... 2016 The Department of Transport Management ... 44 million US Dollar project, for the , ... Personalization, Enrolment, and IT Infrastructure , to ... and implementation of Identity Management Solutions. Numerous renowned international vendors ... Decatur was selected for the most compliant and ...
(Date:5/20/2016)...  VoiceIt is excited to announce its new ... By working together, VoiceIt and VoicePass will offer ... take slightly different approaches to voice biometrics, collaboration ... usability. Both ... "This marketing and technology partnership allows ...
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
Breaking Biology News(10 mins):